Metrics cut 1
- Brownfield capacity expansion (Jubilee Hills, Second Rabbit) slipped from FY27 to FY28–29 due to configuration changes and landlord lease deed delays
Event Participants
Executives
7
Suneeta Reddy (MD), Krishnan Akhileswaran (Group CFO), Madhu Sasidhar (President & CEO, Hospitals Division), Madhivanan Balakrishnan (CEO, Apollo HealthCo), Sriram Iyer (CEO, AHLL), Sanjiv Gupta (CFO, Apollo HealthCo), Obul Reddy (CFO, Pharmacy)
Analysts
10
Binay Singh (Morgan Stanley), Neha Manpuria (BofA Securities), Damyanti Kerai (HSBC), Shyam Srinivasan (Goldman Sachs), Kunal Dhamesha (Macquarie), Vivek Agrawal (Citigroup), Kunal Randeria (Axis Capital), Prashant Kshirsagar (Unived), Tausif Shaikh (BNP Paribas), Rahul Jeewani (IIFL)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Consolidated Revenue | ₹7,043 crores | +21% YoY, broad-based double-digit growth across all three verticals |
| Consolidated EBITDA | ₹1,092 crores | +28% YoY; margin improved 140 bps YoY to 15.5% from 14.6% |
| Consolidated PAT | ₹581 crores | +34% YoY |
| Healthcare Services Revenue | ₹3,567 crores | +22% YoY; established hospitals ₹3,475 crores (+18%), new hospitals ₹92 crores |
| Hospital Volume Growth | 11% | Driven by 13% IP volume growth; pricing +4%, case mix/bed/payer mix +3% |
| Occupancy | 70% | Demand-driven, broad-based across regions; 50% growth in Bangladesh IPS volumes QoQ |
| ARPP | ₹1,86,630 | +8% YoY, reflecting case complexity shift (robotic surgery +85%, transplant volumes rising) |
| Hospital EBITDA Margin | 24.2% | +~50 bps YoY; established hospitals at 25.9% |
| New Hospital EBITDA Loss | ₹38 crores | Ramp-up costs for recently commissioned beds |
| Healthcare Services ROC | 28.5% | Balanced performance across metro, Tier 1 and Tier 2 markets |
| Apollo HealthCo Revenue | ₹2,977 crores | +20% YoY; EBITDA ₹171 crores vs ₹94 crores in Q1 FY26 |
| Digital Cash Loss | ₹10 crores | vs ₹49 crores Q1 FY26 and ₹16 crores Q4 FY26; breakeven expected next quarter |
| Platform GMV | ₹535 crores | +23% YoY; H2 revenues +24% like-for-like after closure of non-profitable corporate partnership |
| AHLL Revenue | ₹499 crores | +15% YoY; EBITDA ₹59 crores (+46%), margin 11.8% vs 9.2% |
| AHLL Diagnostics Revenue | — | +31% YoY; on track for ₹1,000 crores annualized revenue milestone |
| Payer Mix (Insurance + Self-pay) | 83% of IP revenue | Insurance +25% YoY, self-pay +16%; international patients +26% |
| High Acuity (Conquité) Specialties | 62% of IP revenue | Volumes +15%, revenues +24% YoY; cardiac, oncology, transplant, neuro, GI, ortho |
Geographic & Segment Commentary
Healthcare Services (Hospitals): Revenue grew 22% YoY to ₹3,567 crores with established hospitals delivering 18% growth. Volume growth was broad-based across all regions and specialties with no seasonal pattern—elective and semi-elective cases drove the uptick. Conquité specialties (cardiac, oncology, transplant, neurosciences, GI, orthopedics) now contribute 62% of IP revenue, growing 24% YoY, reinforcing the high-acuity leadership positioning. Occupancy at 70% with significant headroom, supported by operational efficiencies and normalization of Bangladesh international patient flows (still at 60–70% of peak volumes but higher complexity per patient).
New Hospitals: Reported revenue of ₹92 crores with EBITDA loss of ₹38 crores. The 180-bed Sarjapur, Bengaluru facility was operationalized during the quarter. Financial District Hyderabad is ramping well and expected to break even next quarter. Bellamus acquisition set to start operations in the coming quarter.
Apollo HealthCo (Pharmacy + Digital): Revenue grew 20% YoY to ₹2,977 crores with EBITDA of ₹171 crores. Pharmacy growth at 25–30%, diagnostics at ~27%, insurance growing ~80% on a small base. Digital cash loss narrowed to ₹10 crores; insurance business remains in investment mode across four call centers (two already CM2 breakeven). Digital vertical expected to reach breakeven in Q2 FY27.
AHLL (Apollo Health & Lifestyle): Revenue grew 15% YoY to ₹499 crores with EBITDA up 46% to ₹59 crores. Diagnostics the key growth engine (+31% revenue, 14% margins) with target of 20% margins over next 6–8 quarters. Primary care growing ~12%; new clinic additions planned. Mother-and-child business transaction concluded, awaiting regulatory clearance from government.
Company-Specific & Strategic Commentary
- Capacity Expansion: 14,100 census beds targeted by FY31 through greenfield expansion in north and west India plus brownfield expansions. Sarjapur Bengaluru (180 beds) operationalized; Gurugram on track for operationalization in FY30 (soft launch September, full opening October). Funding largely from internal accruals with comfortable debt position.
- Digital & Pharmacy Restructuring: Proposed strategic restructuring of omnichannel pharmacy and digital health business on track; multiple regulatory steps proceeding as planned, scheme expected to conclude in current fiscal. Digital vertical achieved significant cost rationalization, on path to breakeven.
- Oncology Leadership: New proton center announced for Delhi (single gantry); Chennai unit (3 gantries) running at near-full capacity on mobile gantries with waitlists. Proton therapy expected to attract top clinical talent and international patients (30% of volumes from overseas).
- Insurance Business Build-out: Corporate agency model leveraging cross-pollination of existing Apollo ecosystem customers; 4 call centers in Gurgaon, Hyderabad (×2), Bangalore; field sales engine being reworked after setback; breakeven targeted by Q3 FY27.
- NPS Vatsalya Opportunity: Early-stage pension-linked healthcare product; PFRDA finalizing regulatory framework; Apollo participated in one of two POCs; meaningful impact expected 12–18 months out.
- Pricing & Parliamentary Committee: Management welcomed government's healthcare spending commitment and focus on governance/transparency but cautioned against one-size-fits-all price controls, arguing they would disincentivize capacity creation and innovation. Apollo maintains ~5% annual price increases in line with medical inflation; insurance contracts reset every two years.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Hospital Revenue Growth | ~20% FY27 | Established hospitals 13–14% + new hospitals contributing ~7% incremental; sustainable over next 24 months |
| New Hospital EBITDA Loss | ~₹150 crores FY27 | Quarterly losses to inch up ~₹20 crores/quarter with new openings, then decline; Financial District Hyderabad to breakeven next quarter |
| Established Hospital EBITDA Margin | ~26% sustainable | Scope for further structural cost takeouts; margins expected to inch up over next 24 months |
| New Hospital Cluster Breakeven | End Q3–Q4 FY28 | Expect overall breakeven of new hospital portfolio by that timeframe |
| Digital Business (Apollo HealthCo) | Breakeven in Q2 FY27 | Core businesses (pharmacy, diagnostics, consults) CM2 positive; insurance achieving breakeven by Q3 FY27 |
| AHLL Diagnostics Margin | 20% in 6–8 quarters | Current 14%; driven by 20%+ revenue growth, scaling, and mix |
| New Hospital Investment | 14,100 beds by FY31 | Funded largely from internal accruals; comfortable debt position |
Risks & Constraints
| Risk | Context |
|---|---|
| Price Regulation / Parliamentary Committee | Government committee recommendations on healthcare pricing could lead to price controls on private providers. Management argued high-quality care comes at a cost and price caps would disincentivize investment; Apollo positions pricing as fair, transparent, and aligned to medical inflation (~5% annually). 70% of patients pay <₹2 lakh per admission; 90% pay <₹5 lakh. |
| Insurance Business Ramp-up | Insurance vertical is the single largest drag on Apollo HealthCo digital breakeven. Field sales engine setback (failed field agent model) delayed progress; costs elevated with four call centers and 250+ workforce. Management targeting breakeven by Q3 FY27 but acknowledged risk of further slippage. |
| New Hospital Ramp-up Execution | ₹150 crores loss guidance for FY27 subject to timing of Bellamus opening and Sarjapur ramp; losses expected to rise ~₹20 crores/quarter before declining. Gurugram opening in FY30 adds future ramp-up costs. Indirect costs already committed can support 750 beds, providing operating leverage once volumes scale. |
| Bangladesh International Patient Recovery | IP volumes from Bangladesh still only 60–70% of pre-crisis peak; normalization contributed meaningfully to Q1 volumes (+50% QoQ) but full recovery remains uncertain. Partially offset by higher patient complexity and 26% international revenue growth. |
| Expansion Delays | Brownfield projects (Jubilee Hills, Second Rabbit) slipped from FY27 to FY28–29 due to configuration changes and landlord lease deed delays; could signal execution friction in capacity program. |
Q&A Highlights
FY27 Hospital Growth Guidance
- Question: With strong Q1 momentum and ramp-up yet to play out, can hospital revenue growth hit closer to 20% this year? (Binay Singh, Morgan Stanley)
- Answer: Management confirmed on track for 20% FY27 growth. Gurugram will soft-launch in September with full opening in October; IP contribution from Q4. New hospital losses will inch up ~₹20 crores per quarter with new openings before declining. Financial District Hyderabad expected to break even in the coming quarter. (Suneeta Reddy, Krishnan Akhileswaran)
Hospital Margin Sustainability
- Question: Established hospital margins near 26%—how much more room for improvement? (Neha Manpuria, BofA Securities)
- Answer: Current margins a good set of numbers; focus is sustaining them first with further cost takeouts possible. Operating leverage from returning IP volumes and cost control measures contributed. New loss guidance of ₹150 crores maintained for FY27; Financial District Hyderabad to breakeven next quarter, Bellamus starting operations next quarter. (Krishnan Akhileswaran)
Digital & Insurance Breakeven Path
- Question: What's driving pre-opex margin improvement in digital, and how long before insurance scales? (Neha Manpuria, BofA; Damyanti Kerai, HSBC)
- Answer: Core businesses (pharmacy at 25–30% growth, diagnostics ~27%) are CM2 positive. Insurance is in build-up mode: four call centers (two breakeven at CM2 level), 250+ workforce, ~80% growth on small base. Setbacks in field sales engine are being reworked; one-time costs from org rationalization increased Q1 expenses. Insurance breakeven targeted by Q3 FY27; sustainable quarterly expenses ~₹80 crores. (Madhivanan Balakrishnan, Sanjiv Gupta)
Proton Therapy Demand & Capacity
- Question: How is Chennai proton center performing, and is there demand for the new Delhi unit? (Damyanti Kerai, HSBC)
- Answer: Chennai (3 gantries: 2 mobile, 1 fixed) running near-full capacity on mobile gantries with waitlists; fixed gantry has some capacity, working extended hours. Scientific literature increasingly supports proton therapy superiority for head/neck cancers; India's high head/neck cancer burden means demand will exceed upcoming supply. Delhi unit (single gantry) will be timely and strengthens comprehensive oncology offering. (Madhu Sasidhar, Suneeta Reddy)
Tamil Nadu Occupancy & Demand Drivers
- Question: Occupancy at 70% in TN is encouraging—seasonal or structural? (Shyam Srinivasan, Goldman Sachs)
- Answer: Demand-driven, not seasonal; no acute febrile illness patterns. Broad-based across medical and surgical admissions, with shift toward elective and semi-elective cases. Bangladesh IP normalization contributed ~50% volume growth QoQ. Higher-acuity patients driving ARPP. (Krishnan Akhileswaran)
GMV vs Revenue Discrepancy in Digital
- Question: GMV growing 23% but revenue growth lagging—how to interpret? (Shyam Srinivasan, Goldman Sachs)
- Answer: Business restructured three quarters ago; revenue now tracks pharmacy and diagnostics GMV (both 25–30% growth). Consult business shifted to flat-fee model as Apollo's digital gateway—revenue will not directly track GMV. CM1 and CM2 margins on pharmacy positive; delivery costs on downward trajectory. (Madhivanan Balakrishnan)
Pricing Scrutiny & Cost Inflation
- Question: With parliamentary committee scrutiny, is ARPP growth sustainable? (Shyam Srinivasan, Goldman Sachs)
- Answer: Pricing is fair, transparent, and aligned with medical inflation (
5% annually); insurance company dialogues (100 hours) were appreciative of the pricing approach. ARPP growth partly reflects case complexity shift (robotic surgery +85%, more transplants), not just tariff increases. 70% of patients pay <₹2 lakh; 90% pay <₹5 lakh per admission, even in metros. (Suneeta Reddy, Krishnan Akhileswaran, Madhu Sasidhar)
New Hospital Indirect Cost Structure
- Question: Is the indirect cost base of new hospitals scalable proportionally as 620+ more beds open? (Kunal Dhamesha, Macquarie)
- Answer: No direct correlation; indirect costs already incurred can support 750 beds at current levels. New bed openings benefit from operating leverage on existing admin and staffing infrastructure. Doctor fees and nursing/paramedic costs are significant components of current new hospital losses. (Krishnan Akhileswaran, Suneeta Reddy)
AHLL Margin Trajectory
- Question: What are margin targets for AHLL and how will they be achieved? (Kunal Randeria, Axis Capital)
- Answer: Diagnostics is the key driver: currently 14% margins, targeting 20% over next 6–8 quarters with 20%+ growth. Primary care growing ~12% with new clinic additions in pipeline. Mother-and-child transaction concluded, awaiting government regulatory clearance; post-merger, focus will double down on diagnostics and primary care. (Sriram Iyer)
International Patient Volumes
- Question: Are Bangladesh volumes fully recovered? (Tausif Shaikh, BNP Paribas)
- Answer: Volume-wise at 60–70% of pre-crisis peak; however, patient complexity is higher, so value per patient is slightly above peak levels. (Krishnan Akhileswaran)
Capacity Expansion Timeline Slippage
- Question: Why did brownfield beds slip from FY27 to FY28–29? (Tausif Shaikh, BNP Paribas)
- Answer: Jubilee Hills expansion moved due to configuration planning changes; Second Rabbit delayed because landlord took time on lease deed. Both now expected next fiscal year. (Krishnan Akhileswaran)
Hospital Closures Rationale
- Question: Apollo closed three facilities (Chennai Tondiarpet, Labasa, Bangladesh)—any material financial impact? (Shubh Kalra, Asit C. Mehta)
- Answer: No material impact. Tondiarpet closed for renovation and upgradation. Labasa is land held for possession, not an operating hospital in the true sense. Bangladesh was an OMA (operation & management agreement) exit. (Suneeta Reddy)
EWS Obligations
- Question: Do Apollo hospitals have Economically Weaker Section bed obligations? (Kunal Dhamesha, Macquarie)
- Answer: EWS obligations exist in select hospitals (Delhi, some in Hyderabad, Calcutta) and are being adhered to. Most Apollo land is freehold, including the upcoming Gurugram facility, limiting obligations compared to peers. Detailed numbers to be shared offline. (Krishnan Akhileswaran)
Key Takeaway
Apollo Hospitals delivered a strong Q1 FY27 with consolidated revenue of ₹7,043 crores (+21% YoY) and EBITDA of ₹1,092 crores (+28%), across all three verticals. Hospital revenue grew 22% with 70% occupancy, 8% ARPP growth, and high-acuity specialties contributing 62% of IP revenue; established hospital EBITDA margin held at 25.9% with management guiding to sustain ~26% while targeting ₹150 crores new hospital losses. Apollo HealthCo narrowed digital cash loss to ₹10 crores and expects digital breakeven in Q2 FY27 and insurance breakeven by Q3 FY27. AHLL grew revenue 15% with diagnostics as the margin engine (target 20% margins in 6–8 quarters). Management guided to ~20% hospital revenue growth for FY27 and 13–14% for established hospitals over next 24 months, backed by capacity expansion to 14,100 beds by FY31. Key watch points include new hospital ramp-up execution, insurance business build-out, parliamentary committee pricing recommendations, and Bangladesh IP volume normalization at 60–70% of peak.
Transcript incomplete - full Q&A section for several analysts (Mayank Vaswani, additional questions) not available in source material.